Mohammad Garakyaraghi

Mohammad Garakyaraghi

Auto-generated profile, based on publicly available information

Mohammad Garakyaraghi

Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AMAhmad Mirdamadi
Ahmad Mirdamadi
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
APAli Pourmoghaddas
Ali Pourmoghaddas
ABAlireza Bahmani
Alireza Bahmani
HMHamideh Mahmoudi
Hamideh Mahmoudi
MGMojgan Gharipour
Mojgan Gharipour
Background.According to the present evidences suggesting association between low testosterone level and prediction of reduced exercise capacity as well as poor clinical outcome in patients with heart failure, we sought to determine if testosterone therapy improves clinical and cardiovascular conditions as well as quality of life status in patients with stable chronic heart failure.Methods.A total of 50 male patients who suffered from congestive heart failure were recruited in a double-blind, placebo-controlled trial and randomized to receive an intramuscular (gluteal) long-acting androgen injection (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks or receive intramuscular injections of saline (1 mL of 0.9% wt/vol NaCl) with the same protocol.Results.The changes in body weight, hemodynamic parameters, and left ventricular dimensional echocardiographic indices were all comparable between the two groups. Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P=0.019). The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262,Findex = 4.402, andP=0.045).Conclusion.Our study strengthens insights into the beneficial role of testosterone in improvement of functional capacity and quality of life in heart failure patients.

1 May 2009
Verified
Journal Article
Closed access
STShahram Taheri
Shahram Taheri
MMMojgan Mortazavi
Mojgan Mortazavi
SSSiamak Shahidi
Siamak Shahidi
APAli Pourmoghadas
Ali Pourmoghadas
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
MGMaryam Ghassami
Maryam Ghassami

29 December 2013 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
MSMasoumeh Sadeghi
Masoumeh Sadeghi
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
MKMohsen Khosravi
Mohsen Khosravi
MTMahboobeh Taghavi
Mahboobeh Taghavi
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
HRHamidreza Roohafza
Hamidreza Roohafza
Introduction. The accurate impact of exercise on coronary artery disease (CAD) patients with left ventricular dysfunction is still debatable. We studied the effects of cardiac rehabilitation (CR) on echocardiography parameters in CAD patients with ventricular dysfunction.Methods. Patients with CAD who had ventricular dysfunction were included into an exercise-based rehabilitation program and received rehabilitation for eight weeks. All subjects underwent echocardiography before and at the end of the rehabilitation program. The echocardiography parameters, including left ventricular ejection fraction (LVEF), LV end-diastolic (LVEDD) and end-systolic diameters (LVESD), and peak exercise capacity measured in metabolic equivalents (METs), were assessed.Results. Seventy patients (mean age = 57.5 ± 10.2 years, 77.1% males) were included into the study. At the end of rehabilitation period, the LVEF increased from 45.14 ± 5.77% to 50.44 ± 8.70% (P<0.001), and the peak exercise capacity increased from 8.00 ± 2.56 to 10.08 ± 3.00 METs (P<0.001). There was no significant change in LVEDD (54.63 ± 12.96 to 53.86 ± 8.95 mm,P=0.529) or in LVESD (38.91 ± 10.83 to 38.09 ± 9.04 mm,P=0.378) after rehabilitation.Conclusion. Exercise training in postmyocardial infarction patients with ventricular dysfunction could have beneficial effects on cardiac function without adversely affecting LV remodeling or causing serious cardiac complications.

1 September 2017
Verified
Journal Article
Open access
MGMahshid Givi
Mahshid Givi
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
GYGhasem Yadegarfar
Ghasem Yadegarfar
MSMasoumeh Sadeghi
Masoumeh Sadeghi
MSMohammad Reza Sabri
Mohammad Reza Sabri
BACKGROUND: Our aim was to create and establish a database called "Persian Registry Of cardioVascular diseasE (PROVE)" in order to be used for future research and in addition, as a tool to develop national guidelines for diagnosis, treatment, and prevention of cardiovascular disease (CVD). In this paper, the design and methodology of the PROVE pilot study will be discussed, launched in Isfahan, Iran, in 2015-2016. METHODS: Through establishing PROVE, patients' data were collected from hospitals and outpatient clinics prospectively or retrospectively and followed up for a maximum of three years based on the type of CVDs. The inclusion criteria were as patients with acute coronary syndrome (ACS), ST elevation myocardial infarction (STEMI), stroke, atrial fibrillation (AF), heart failure (HF), congenital heart disease (CHD), percutaneous coronary intervention (PCI), and chronic ischemic cardiovascular disease (CICD). Specific protocols, questionnaires, and glossaries were developed for each registry. In order to ensure the validation of the protocols, questionnaires, data collection, management, and analysis, a well-established quality control (QC) protocol was developed and implemented. Data confidentiality was considered. RESULTS: In order to register patients with ACS, STEMI, stroke, HF, PCI, and CICD, the hospital recorded data were used, whereas, in case of AF and CHD registries, the data were collected from hospitals and outpatient clinics. During the pilot phase of the study in Isfahan, from March 2015 to September 2016, 9427 patients were registered as ACS including 809 as STEMI, 1195 patients with HF, 363 with AF, 761 with stroke, 1136 with CHD, 1200 with PCI, and 9 with CICD. Data collection and management were performed under the supervision of the QC group. CONCLUSION: PROVE was developed and implemented in Isfahan as a pilot study, in order to be implemented at national level in future. It provides a valuable source of valid data that could be used for future research, re-evaluation of current CVD management and more specifically, gap analysis and as a tool for assessment of the type of CVDs, prevention, treatment, and control by health care decision makers.

1 September 2015 in Rehabilitation Nursing Journal
Verified
Journal Article
Closed access
MSMasoumeh Sadeghi
Masoumeh Sadeghi
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
MTMahboobeh Taghavi
Mahboobeh Taghavi
MKMohsen Khosravi
Mohsen Khosravi
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
HRHamidreza Roohafza
Hamidreza Roohafza

30 March 2018 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
MGMahshid Givi
Mahshid Givi
DSDavood Shafie
Davood Shafie
FNFatemeh Nouri
Fatemeh Nouri
MGMohammad Garakyaraghi
Mohammad Garakyaraghi
GYGhasem Yadegarfar
Ghasem Yadegarfar
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
Objectives Heart failure (HF) has a high rate of hospitalisation and mortality. We examined its risk factors, survival rate and the predictors. Methods In this prospective cohort study, demographic, clinical and treatment data of 1223 patients hospitalised with HF were extracted from the Persian Registry Of cardio Vascular diseasE (PROVE)/HF registry. Survival rate and HR and their association with other variables were assessed. Results 835 (68.3%) were censored, while 388 (31.7%) patients were deceased. Mean age and frequency of hypotension during hospitalisation, tachycardia, pulmonary hypertension and anaemia, hyponatremia, heart valve disease and renal disease of the deceased patients was significantly higher than censored patients (15.2vs6.1%, 51.1vs40.1%, 24.4vs16.7%, 39.0vs31.8%, respectively, p<0.05). ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) (89.8%vs82.1%, respectively) and beta blocker (BB) (81.1%vs75.5%, respectively) were higher in follow–up in the censored group (p1) and using ACEI/ARB and BB as predictors of life (HR <1, p<0.05). After adjustment, all variables lost their significance, except BB (HR 0.63, p=0.03) and tachycardia (HR 1.74, p=0.01) and New York Heart Association (NYHA) class IV (HR 1.90, p=0.04) became significant predictors. Conclusions We found a high mortality rate (31.7%). As NYHA class IV and tachycardia were significant predictors of mortality after adjustment, an effective measure can be treatment of underlying diseases, which deteriorate patients’ conditions. Monitoring of medications for at–risk group, especially BB that predicts life, is important.